Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

Lessons Learned The lack of efficacy associated with anti‐EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non‐small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Jg. 23; H. 6; S. 654 - e58
Hauptverfasser:	von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States AlphaMed Press 01.06.2018
Schlagworte:	Clinical Trial Results
ISSN:	1083-7159, 1549-490X, 1549-490X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!